JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement
AbbVie and RemeGen have signed the first deal of the J.P Morgan Healthcare Conference 2026, with the companies agreeing to …
Post
-
-
JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax
Eli Lilly is reportedly looking to acquire French biotech Abivax, sending the latter company’s shares surging ahead of the J.P. …
-
FDA increases manufacturing flexibility for cell and gene therapies
The US Food and Drug Administration (FDA) has announced increased flexibility for cell and gene therapy (CGT) manufacturers, loosening quality …
-
The value of real-world data for healthcare marketing
Marketing has evolved significantly since the time when a marketing plan would ignore market segment differences and appeal to the …
-
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree
Revolution Medicines has dominated the build-up to the 2026 J.P. Morgan Healthcare Conference, as media reports swirl around a potential …
-
Novartis to build fourth US radioligand therapy facility in Florida
Novartis has announced plans to construct a radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its …
-
MediLink and Roche announce exclusive licensing agreement for YL201
MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of YL201, an investigational antibody-drug …
-
US comes up with two mandatory IRP use pricing models under Trump’s MFN strategy
Just before Christmas 2025, the US Centers for Medicare and Medicaid Services (CMS) unveiled two pricing models based on the …
-
Managing supply chain challenges for CDMOs
Pharma supply chains are under enormous pressure globally, with geopolitical tensions and the issue of tariffs requiring careful management by …
-
Alveus debuts in obesity arena with $160m Series A
Alveus Therapeutics has debuted with $160m in Series A financing, as the biotech looks to join the crowded obesity sector …
-
J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts
Johnson & Johnson (J&J) has become the latest in a stream of pharma companies to sign a drug pricing deal …
-
Takeda and Halozyme sign global agreement for Enhanze technology
Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter’s Enhanze drug …
-
Bile acid modulators in discovery: Identifying cholestasis candidates with the best chance of success
Disrupted bile flow, or cholestasis, is a key feature of various chronic liver diseases such as primary biliary cholangitis (PBC) …
-
Santhera grants Agamree rights to Nxera for DMD
Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) …
-
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
Eli Lilly has agreed to acquire autoimmune oral drug developer Ventyx Biosciences, representing the big pharma company’s latest push to …
